• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CARA

    Cara Therapeutics Inc.

    Subscribe to $CARA
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: caratherapeutics.com

    Recent Analyst Ratings for Cara Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    6/13/2024Buy → Hold
    Needham
    6/13/2024Buy → Neutral
    H.C. Wainwright
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    3/8/2022$17.00 → $20.00Neutral → Overweight
    JP Morgan
    11/1/2021$33.00Buy
    Canaccord Genuity
    8/24/2021$33.00 → $35.00Buy
    HC Wainwright & Co.
    8/3/2021$16.00Neutral
    JP Morgan
    See more ratings

    Cara Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cara Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

      6/13/24 7:05:24 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

      6/13/24 7:05:04 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Needham

      Needham downgraded Cara Therapeutics from Buy to Hold

      6/13/24 7:04:33 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Cara Therapeutics from Buy to Neutral

      6/13/24 7:04:02 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cara Therapeutics from Neutral to Underperform and set a new price target of $6.00 from $13.00 previously

      3/8/23 7:20:14 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Cara Therapeutics from Neutral to Overweight and set a new price target of $20.00 from $17.00 previously

      3/8/22 5:13:40 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Cara Therapeutics with a new price target

      Canaccord Genuity resumed coverage of Cara Therapeutics with a rating of Buy and set a new price target of $33.00

      11/1/21 8:34:55 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cara Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Cara Therapeutics with a rating of Buy and set a new price target of $35.00 from $33.00 previously

      8/24/21 6:11:11 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Cara Therapeutics with a new price target

      JP Morgan initiated coverage of Cara Therapeutics with a rating of Neutral and set a new price target of $16.00

      8/3/21 5:08:48 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Cara Therapeutics with a new price target

      Needham reiterated coverage of Cara Therapeutics with a rating of Buy and set a new price target of $26.00 from $35.00 previously

      4/29/21 12:22:10 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cara Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

      Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

      8/24/21 12:36:58 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cara Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Cara Therapeutics Inc.

      SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

      10/30/24 4:21:50 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/13/24 6:50:36 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/13/24 5:01:02 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      7/25/23 4:40:49 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/9/23 11:12:42 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cara Therapeutics Inc.

      SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)

      11/18/22 4:16:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/14/22 11:35:51 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cara Therapeutics Inc.

      SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/9/22 3:33:31 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics, Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      10/21/21 4:15:59 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/16/21 2:41:57 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cara Therapeutics Inc. Financials

    Live finance-specific insights

    See more

    Cara Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

      –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

      3/4/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

      STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co

      2/12/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

      – Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce reduction of up to 50% – – Cara ended 2023 with approximately $101 million in cash; runway extended into 2026 – – Company to host conference call and webcast today at 8:30 a.m. EST – STAMFORD, Conn., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the

      1/22/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Reports Third Quarter 2023 Financial Results

      – Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated within current financial runway – – Topline results from Part A of KIND 1 Phase 3 atopic dermatitis trial expected in December 2023 – – 3Q23 total revenue of $4.9M including collaborative revenue of $1.9M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Conference call today at 4:30 p.m. EST – STAMFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new t

      11/13/23 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

      STAMFORD, Conn., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 13, 2023, at 4:30 p.m. ET to report third quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company'

      10/23/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Reports Second Quarter 2023 Financial Results

      – 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS proposed rule suggests additional funding for TDAPA-designated products in existing functional category; final rule expected in 4Q23 – – Three late-stage oral difelikefalin clinical programs tracking to plan; Internal readout of Part A of KIND 1 atopic dermatitis trial expected in 4Q23 – – Conference call today at 4:30 p.m. EDT – STAMFORD, Conn., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercia

      8/7/23 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

      STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's

      7/24/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Reports First Quarter 2023 Financial Results

      – 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than doubling quarter to quarter – – Three late-stage oral difelikefalin clinical programs progressing with internal readout of Part A of KIND 1 AD trial on track for 4Q23 – – Conference call today at 4:30 p.m. EDT – STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announc

      5/15/23 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

      STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the News & Investors section of the Company

      5/1/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

      STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her

      8/3/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Appointment of Christopher Posner as New Independent Director

      24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

      11/29/22 7:30:00 AM ET
      $CARA
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

      STAMFORD, Conn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Lisa von Moltke, M.D., to its Board of Directors. Dr. von Moltke currently serves as Executive Vice President and Chief Medical Officer at Seres Therapeutics, Inc. "We are very pleased to welcome Lisa to our board of directors," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "Her extensive clinical development and pharmacology expertise will be of great value as we continue executing o

      11/3/22 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cara Therapeutics Announces CEO Transition

      STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, a current member of the Company's Board of Directors, has been appointed President and Chief Executive Officer, effective November 9, 2021. Mr. Posner succeeds Dr. Derek Chalmers, who will transition to a Senior Advisor role. Mr. Posner joins the Company from LEO Pharma, Inc., the US affiliate of LEO Pharma A/S, a global leader in medical dermatology, where he was President and CE

      11/3/21 8:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

      SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy. “We are pleased to welcome Mani to CytomX’s board of directors,” commented Sean McCarthy, D.Phil., president, chief executive officer (CEO) and chairman of CytomX. “Mani brings a

      12/22/20 4:05:00 PM ET
      $CARA
      $CTMX
      $CRIS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • SAB Biotherapeutics Announces New Appointments to its Board of Directors

      SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors. “We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a p

      12/16/20 7:27:00 AM ET
      $CRIS
      $CARA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    Cara Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

      STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara's common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name "Tvardi Therapeutics, Inc." and under the new symbol "TVRD" following the anticipated closing of the merger (the "Merger") with Tvard Therapeutics, Inc. ("Tvardi"), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara's stockholders at Cara's special

      4/14/25 11:50:29 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

      STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1

      12/27/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Exploration of Strategic Alternatives

      STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. "We are committed to evaluating a range of strategic options to maximize value for our shareholders," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "As part of this effort, our Board of Directors has approved a streamlined operating plan focused on cost-containment and cash conservation." There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or

      7/11/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

      – Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP). Oral difelikefalin did not demonstrate a meaningful clinical benefit at

      6/12/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Reports First Quarter 2024 Financial Results

      STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. "Our notalgia paresthetica (NP) pivotal clinical program is progressing ahead of schedule and we now expect to report topline efficacy and safety results from KOURAGE 1 Part A by the end of the second quarter of 2024," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "We believe the medical dermatology community's intere

      5/13/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

      STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under "Press Releases" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is dev

      5/6/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

      STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutic

      4/2/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

      STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled "Meet the NP Experts" on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemiology, diagnosis, treatment landscape, and significant unmet medical need in notalgia paresthetica (NP). The live panel discussion will be moderated by Joana Goncalves, MD, Chief Medical Officer of Cara Th

      3/7/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

      –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

      3/4/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cara Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:20 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:30 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by VP, Chem, Mfg and Ctrls Chen Yixin

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:27 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:22 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shiff Susan Ph.D.

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:17 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:25 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Cynthia

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:11 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wirk Shaheen

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:15 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shah Sujal

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:08 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cara Therapeutics Inc. SEC Filings

    See more
    • Cara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure, Other Events

      8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      4/15/25 4:06:29 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/11/25 4:16:03 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/1/25 4:30:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Cara Therapeutics Inc.

      425 - Cara Therapeutics, Inc. (0001346830) (Subject)

      3/24/25 4:30:36 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      3/24/25 4:30:17 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Cara Therapeutics Inc.

      10-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      3/11/25 4:10:43 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Cara Therapeutics Inc.

      EFFECT - Cara Therapeutics, Inc. (0001346830) (Filer)

      2/18/25 12:15:10 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Cara Therapeutics Inc.

      424B3 - Cara Therapeutics, Inc. (0001346830) (Filer)

      2/14/25 5:13:51 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Cara Therapeutics Inc.

      S-4/A - Cara Therapeutics, Inc. (0001346830) (Filer)

      2/14/25 6:01:06 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-4/A filed by Cara Therapeutics Inc.

      S-4/A - Cara Therapeutics, Inc. (0001346830) (Filer)

      1/27/25 6:19:42 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care